Advances in the delivery of RNA therapeutics: from concept to clinical reality
Name
13073_2017_Article_450.pdf
Size
675.8 KB
Format
Adobe PDF
Checksum (MD5)
fdbc2487263880e10eacfe708afa4c0c
Author(s) • •
Kaczmarek, James Cliff
Kowalski, Piotr S
Anderson, Daniel Griffith
Date Issued
June 2017
Journal
Genome Medicine
Publisher
BioMed Central
Citation
Kaczmarek, James C., Piotr S. Kowalski, and Daniel G. Anderson. “Advances in the Delivery of RNA Therapeutics: From Concept to Clinical Reality.” Genome Medicine 9, no. 1 (June 27, 2017).
Version
Final published version
Abstract
Abstract - The rapid expansion of the available genomic data continues to greatly impact biomedical science and medicine. Fulfilling the clinical potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including short interfering RNAs and antisense oligonucleotides, are particularly promising examples of this newer class of biologics. For over two decades, researchers have been trying to overcome major challenges for utilizing such RNAs in a therapeutic context, including intracellular delivery, stability, and immune response activation. This research is finally beginning to bear fruit as the first RNA drugs gain FDA approval and more advance to the final phases of clinical trials. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field. In this review, we discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene/protein expression and genome editing that are currently being investigated both in the laboratory as well as in the clinic.
MIT Department
Koch Institute for Integrative Cancer Research
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1186/s13073-017-0450-0